Send to

Choose Destination
J Rheumatol. 1992 Sep;19(9):1403-6.

Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.

Author information

Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK.


Iloprost is a chemically stable analog of prostaglandin I2 showing the same properties as the naturally occurring substance, but with advantages of ease of handling and administration to patients. A double blind within patient comparison of intravenous iloprost and placebo was undertaken in 13 patients with Raynaud's phenomenon severe enough to warrant short term hospitalization for intravenous dilator therapy; thermography was used as one form of assessment. Our results, while showing improvements in frequency of Raynaud's attacks after iloprost compared with placebo, show no significant effects on other variables.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center